PF-Atlas › Clinical Trials › NCT00694850

Impact of Multiple Doses of BAY63-2521 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Patients With Interstitial Lung Disease Associated Pulmonary Hypertension

Riociguat . · Phase 2

Registry ID

NCT00694850

Phase

Phase 2

Status

Completed

Drug / intervention

Riociguat (Adempas, BAY63-2521).

Sponsor

Bayer

Start

2008-08-02

About this trial

Riociguat . is evaluated in NCT00694850, a Phase 2 idiopathic pulmonary fibrosis study sponsored by Bayer. Current status: Completed.

View NCT00694850 on ClinicalTrials.gov →

Explore related

All Riociguat . trials All IPF trials

Medical disclaimer. This page summarizes public trial data for NCT00694850 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.